

**Experiment Number:** 88073-04  
**Test Type:** 26-WEEK  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**

**Test Compound:** 2',3'-Dideoxycytidine

**CAS Number:** 7481-89-2

**Date Report Requested:** 10/18/2014

**Time Report Requested:** 15:29:09

**First Dose M/F:** NA / NA

**Lab:** SRI

<b>C Number:</b>	C88073C
<b>Lock Date:</b>	07/25/1995
<b>Cage Range:</b>	All
<b>Date Range:</b>	All
<b>Reasons For Removal:</b>	All
<b>Removal Date Range:</b>	All
<b>Treatment Groups:</b>	All
<b>Study Gender:</b>	Both
<b>PWG Approval Date</b>	NONE

**Experiment Number:** 88073-04  
**Test Type:** 26-WEEK  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
**Test Compound:** 2',3'-Dideoxycytidine  
**CAS Number:** 7481-89-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 15:29:09  
**First Dose M/F:** NA / NA  
**Lab:** SRI

B6C3F1 Mouse MALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
<b>Disposition Summary</b>				
<b>Animals Initially In Study</b>	50	50	50	50
<b>Early Deaths</b>				
<b>Moribund Sacrifice</b>		1		
<b>Survivors</b>				
<b>Terminal Sacrifice</b>	50	49	50	50
<b>Animals Examined Microscopically</b>	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Liver	(50)	(50)	(50)	(50)
Lymphoma Malignant			3 (6%)	
<b>CARDIOVASCULAR SYSTEM</b>				
None				
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(49)	(50)	(49)	(49)
Lymphoma Malignant			1 (2%)	
Adrenal Medulla	(49)	(50)	(49)	(49)
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
None				
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)	
Lymph Node	(0)	(0)	(1)	(0)
Iliac, Lymphoma Malignant			1 (100%)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

Experiment Number: 88073-04

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/18/2014

Time Report Requested: 15:29:09

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse MALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Inguinal, Lymphoma Malignant			1 (100%)	
Lymphoma Malignant			1 (100%)	
Mediastinal, Lymphoma Malignant			1 (100%)	
Renal, Lymphoma Malignant			1 (100%)	
Lymph Node, Mesenteric Lymphoma Malignant	(49)	(50)	(50)	(50)
Spleen Lymphoma Malignant	(50)	(50)	(50)	(50)
Thymus Lymphoma Malignant	(49)	(50)	(49)	(50)
		3 (6%)	7 (14%)	4 (8%)
INTEGUMENTARY SYSTEM				
Skin Squamous Cell Papilloma	(0)	(0)	(0)	(1) 1 (100%)
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
None				
RESPIRATORY SYSTEM				
Lung Alveolar/Bronchiolar Adenoma Lymphoma Malignant	(50) 1 (2%)	(50) 1 (2%)	(50) 1 (2%) 3 (6%)	(50) 1 (2%)
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
Kidney Lymphoma Malignant	(0)	(0)	(1) 1 (100%)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

**Experiment Number:** 88073-04

**Test Type:** 26-WEEK

**Route:** GAVAGE

**Species/Strain:** Mouse/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**

**Test Compound:** 2',3'-Dideoxycytidine

**CAS Number:** 7481-89-2

**Date Report Requested:** 10/18/2014

**Time Report Requested:** 15:29:09

**First Dose M/F:** NA / NA

**Lab:** SRI

---

<b>B6C3F1 Mouse MALE</b>	<b>VEHICLE</b>	<b>500 MG/KG/DY</b>	<b>1000 MG/KG/DY</b>	<b>1000 MG/KG/DY</b>
SYSTEMIC LESIONS				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Lymphoma Malignant		3 (6%)	8 (16%)	4 (8%)

---

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

Experiment Number: 88073-04  
Test Type: 26-WEEK  
Route: GAVAGE  
Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
Test Compound: 2',3'-Dideoxycytidine  
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014  
Time Report Requested: 15:29:09  
First Dose M/F: NA / NA  
Lab: SRI

---

B6C3F1 Mouse MALE	VEHICLE	500	MG/KG/DY	1000	MG/KG/DY	1000	MG/KG/DY
<b>Tumor Summary for MALE</b>							
Total Animals with Primary Neoplasms (b)	1	4		9		6	
Total Primary Neoplasms	1	4		9		6	
Total Animals with Benign Neoplasms	1	1		1		2	
Total Benign Neoplasms	1	1		1		2	
Total Animals with Malignant Neoplasms		3		8		4	
Total Malignant Neoplasms		3		8		4	
Total Animals with Metastatic Neoplasms							
Total Metastatic Neoplasms							
Total Animals with Malignant Neoplasms Uncertain Primary Site							
Total Animals with Neoplasms Uncertain - Benign or Malignant							
Total Uncertain Neoplasms							

---

\*\*\*END OF MALE DATA\*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

Experiment Number: 88073-04  
 Test Type: 26-WEEK  
 Route: GAVAGE  
 Species/Strain: Mouse/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
**Test Compound:** 2',3'-Dideoxycytidine  
**CAS Number:** 7481-89-2

Date Report Requested: 10/18/2014  
 Time Report Requested: 15:29:09  
 First Dose M/F: NA / NA  
 Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
<b>Disposition Summary</b>				
Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice			3	4
Natural Death				1
Survivors				
Moribund Sacrifice				1
Terminal Sacrifice	50	50	47	44
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Liver	(50)	(50)	(50)	(50)
Lymphoma Malignant			3 (6%)	10 (20%)
Mesentery	(0)	(0)	(0)	(1)
Pancreas	(0)	(0)	(0)	(1)
<b>CARDIOVASCULAR SYSTEM</b>				
None				
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(49)	(50)	(50)	(50)
Lymphoma Malignant			1 (2%)	1 (2%)
Adrenal Medulla	(48)	(50)	(50)	(50)
<b>GENERAL BODY SYSTEM</b>				
None				
<b>GENITAL SYSTEM</b>				
Ovary	(50)	(50)	(50)	(50)
Lymphoma Malignant			3 (6%)	8 (16%)
Uterus	(7)	(7)	(6)	(1)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

**Experiment Number:** 88073-04  
**Test Type:** 26-WEEK  
**Route:** GAVAGE  
**Species/Strain:** Mouse/B6C3F1

**P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)**  
**Test Compound:** 2',3'-Dideoxycytidine  
**CAS Number:** 7481-89-2

**Date Report Requested:** 10/18/2014  
**Time Report Requested:** 15:29:09  
**First Dose M/F:** NA / NA  
**Lab:** SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Lymphoma Malignant				1 (100%)
Polyp Stromal		1 (14%)	3 (50%)	
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Lymphoma Malignant			4 (8%)	6 (12%)
Lymph Node	(1)	(0)	(3)	(2)
Iliac, Lymphoma Malignant			2 (67%)	1 (50%)
Inguinal, Lymphoma Malignant			2 (67%)	1 (50%)
Lymphoma Malignant			2 (67%)	1 (50%)
Mediastinal, Lymphoma Malignant			2 (67%)	1 (50%)
Renal, Lymphoma Malignant			3 (100%)	2 (100%)
Lymph Node, Mandibular	(0)	(0)	(2)	(4)
Lymphoma Malignant			2 (100%)	4 (100%)
Lymph Node, Mesenteric	(50)	(50)	(50)	(49)
Lymphoma Malignant			3 (6%)	5 (10%)
Spleen	(50)	(50)	(50)	(50)
Lymphoma Malignant			3 (6%)	7 (14%)
Thymus	(50)	(50)	(50)	(49)
Lymphoma Malignant		1 (2%)	24 (48%)	19 (39%)
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(0)	(2)	(3)	(2)
<b>MUSCULOSKELETAL SYSTEM</b>				
None				
<b>NERVOUS SYSTEM</b>				
Brain	(0)	(0)	(0)	(1)
<b>RESPIRATORY SYSTEM</b>				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically

Experiment Number: 88073-04

Test Type: 26-WEEK

Route: GAVAGE

Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)

Test Compound: 2',3'-Dideoxycytidine

CAS Number: 7481-89-2

Date Report Requested: 10/18/2014

Time Report Requested: 15:29:09

First Dose M/F: NA / NA

Lab: SRI

B6C3F1 Mouse FEMALE	VEHICLE	500 MG/KG/DY	1000 MG/KG/DY	1000 MG/KG/DY
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma				1 (2%)
Lymphoma Malignant			4 (8%)	10 (20%)
SPECIAL SENSES SYSTEM				
None				
URINARY SYSTEM				
Kidney	(0)	(0)	(2)	(4)
Lymphoma Malignant			2 (100%)	4 (100%)
SYSTEMIC LESIONS				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Lymphoma Malignant		1 (2%)	24 (48%)	19 (38%)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically



Experiment Number: 88073-04  
Test Type: 26-WEEK  
Route: GAVAGE  
Species/Strain: Mouse/B6C3F1

P02: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)  
Test Compound: 2',3'-Dideoxycytidine  
CAS Number: 7481-89-2

Date Report Requested: 10/18/2014  
Time Report Requested: 15:29:09  
First Dose M/F: NA / NA  
Lab: SRI

---

B6C3F1 Mouse FEMALE	VEHICLE	500	MG/KG/DY	1000	MG/KG/DY	1000	MG/KG/DY
<b>Tumor Summary for FEMALE</b>							
Total Animals with Primary Neoplasms (b)		2		26		20	
Total Primary Neoplasms		2		27		20	
Total Animals with Benign Neoplasms		1		3		1	
Total Benign Neoplasms		1		3		1	
Total Animals with Malignant Neoplasms		1		24		19	
Total Malignant Neoplasms		1		24		19	
Total Animals with Metastatic Neoplasms							
Total Metastatic Neoplasms							
Total Animals with Malignant Neoplasms Uncertain Primary Site							
Total Animals with Neoplasms Uncertain - Benign or Malignant							
Total Uncertain Neoplasms							

---

\*\* END OF REPORT \*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

\* Number of animals with any tissue examined microscopically